STP705 for Facial isSCC

Phase-Based Progress Estimates
Center for Clinical and Cosmetic Research, Aventura, FL
Facial isSCC+1 More
STP705 - Drug
All Sexes
What conditions do you have?

Study Summary

Open label, dose escalation to evaluate safety.

Eligible Conditions

  • Facial isSCC

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Facial isSCC

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 21 weeks

21 weeks
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Proportion of participants with histological clerance of treated isSCC lesion at the end of treatment

Trial Safety

Safety Progress

1 of 3

Other trials for Facial isSCC

Trial Design

3 Treatment Groups

STP705 90ug
1 of 3
STP705 60ug
1 of 3
STP705 30ug
1 of 3
Experimental Treatment

30 Total Participants · 3 Treatment Groups

Primary Treatment: STP705 · No Placebo Group · Phase 1 & 2

STP705 90ug
Experimental Group · 1 Intervention: STP705 · Intervention Types: Drug
STP705 60ug
Experimental Group · 1 Intervention: STP705 · Intervention Types: Drug
STP705 30ug
Experimental Group · 1 Intervention: STP705 · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 21 weeks
Closest Location: Center for Clinical and Cosmetic Research · Aventura, FL
Photo of florida 1Photo of florida 2Photo of florida 3
2013First Recorded Clinical Trial
1 TrialsResearching Facial isSCC
15 CompletedClinical Trials

Who is running the clinical trial?

SirnaomicsLead Sponsor
10 Previous Clinical Trials
425 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
You are able to follow study instructions and likely to complete all study requirements.
You have given written consent to allow photographs of the target to be used as part of the study data and documentation.
You are a male or female adult ≥ 18 years of age.
The study requires that you have no medical conditions that would interfere with the study.
You have provided written informed consent for tissue to be examined and stored by the Central Histology Lab.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.